Means for correcting insulin resistance


(57) Abstract:

The invention relates to the field of medicine. The invention consists in the application of Mexidol (2-ethyl-6-methyl-3-oksipiridina succinate) as a means for the correction of insulin resistance. Mexidol can improve the effectiveness of hypoglycemic and hypolipidemic drugs, because it has a direct effect on carbohydrate and lipid metabolism. A wide range of pharmacological activity of Mexidol allows to reduce the number entered in the complex with it's antibacterial, anti-inflammatory, fibrinolytic, anxiolytic, antidiabetic drugs, as well as the means of correcting lipid metabolism, which helps to reduce the frequency of adverse reactions. table 2.

The invention relates to the field of experimental and clinical medicine.

In many pathological conditions the body's sensitivity to insulin is reduced. So, it is celebrated in a variety of infections, acute and chronic inflammatory processes, burn injuries, schizophrenia, diseases of the blood, the hypothyrosis according to, thyrotoxicosis, the syndrome polikistozy ovaries, obesity, aging, diabetes, cardio-sosudistom disease // Physiol-Rev. - 1995 - Jul; 75(3): 473-86)

Insulin resistance (IR) can be defined as a condition in which at physiological concentrations of insulin, there is a decrease in the consumption of glucose by tissues. Insufficient consumption of glucose by the tissues leads to stimulation of cells and the development of compensatory hyperinsulinemia. The most important pathogenetic link IL is to increase the level of free fatty which can decrease insulin sensitivity and activate gluconeogenesis (Boden G. 1998. Free fatty acids (FFA), a link between obesity and insulin resistance. Frontiers in Bioscience 3, 169-175). Key factors of this syndrome are hyperglycemia, hyperinsulinemia, dyslipidemia (hypertriglyceridemia, hypercholesterolemia, increased low-density lipoproteins and decrease high-density lipoproteins) (G. Boden Role of fatty acids in the pathogenesis of insulin resistance and NIDDM // Diabetes -1997. - Vol. 46-N. 1 - P. 3-9), arterial hypertension.

Known drugs, correcting lipid metabolism: statins are inhibitors of HMG-COA reductase (mevacor, pravastatin, simvastatin), derived fibre acid (clofibrate, fenofibrate, bezafibrat, gemfibrozil), nicotinic acid and its derivatives (enduracin, acipimox), anion exchange resins (colestipol, cholestyramine, probase to a greater or lesser extent, reduce the level of triglycerides, the very low density lipoproteins, low-density lipoprotein and total cholesterol, increasing high-density lipoproteins. However, these drugs require constant use, which can lead to significant side effects: myositis, rhabdomyolysis (fibrates), a persistent elevation of transaminases ALT and AST, insomnia, convulsions, paraesthesia (statins), expansion of blood vessels of the face and the upper half of the body, hyperglycemia (nicotinic acid), obstipation, dyspepsia (anion exchange resin) (Lipid metabolism disorders and coronary heart disease: primary prevention, diagnosis, and therapy guidelines for general practice // G. Assman (Ed.). 2.,enl. Ed. - Munchen: MMV-Medizin-Verl.,1993, p. 115-128).

For the correction of insulin resistance is also used biguanides (Metformin) or thiazolidinedione derivatives (troglitazone, rezulin), dose and dosing frequency of which varies depending on the level of glycemia (Saltiel A. L., Olefsky J. M. Thiazolidionediones in the treatment of insulin resistance and type II diabetes // Diabetes - 1996 - Vol.45-N. 12-P. 1661 - 1669)

However, the use of these drugs has a number of disadvantages. Biguanides are of limited use in the pathology of the kidney, in addition, they can cause lactic acidosis. With long-term use of these drugs occurs a decrease in sensitivity to them, about the effectiveness of troglitazone (rezulin) in the correction of insulin resistance in obesity, diabetes mellitus type II, hypertension, however, this drug has not yet been applied in patients with chronic and acute inflammatory diseases acute surgical diseases (chronic and acute destructive pancreatitis, peritonitis), has not yet received information about long-term use of this drug, in addition, the drug is contraindicated in liver (Nolan J. J., Ludvik Century, E. Beerdsen et al. Improvement in glucose tolerance and insulin resistance in obese subjects, treated with troglitazone //N. Engl. J. Mec. -1994-331-P. 1188-1193).

For the correction of insulin resistance in diabetes type 2 diabetes use insulin short and long-term actions, and dosage and administration frequency select only under the control of glycemia (Yki-Jarvinen H., Kaupi la m, Kujansuu E. et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus // N. Engl. J. Med. - 1992 - Vol.327 - P. 426-1433).

However, the use of insulin for correction of insulin resistance in diabetes mellitus type 2 has several disadvantages: multiple times during the day introduction of insulin requires a well-regulated diet and amount of physical activity; the need for continuous and frequent monitoring of blood glucose for adequate insulin therapy; the use of high doses of insulin in the background already the MENA, and, therefore, may not be the best way to relieve insulin resistance. Increased risk of developing acute vascular disease (myocardial infarction, stroke) questioned the necessity of the use of insulin for correction of R & d, especially in patients of advanced age.

Mexidol (2-ethyl-6-methyl-3-oksipiridina succinate) is an antihypoxic drug, an inhibitor of free-radical processes, has strong anti-inflammatory and antibacterial properties, antiamnesic and anxiolytic action. Mexidol was used for the treatment of acute disorders of cerebral circulation, discirculatory encephalopathy, vascular dystonia, atherosclerotic disorders of brain function, neurotic disorders, inflammatory processes of different etiology.

Mexidol was not previously used as a means for the correction of insulin resistance, despite the low toxicity and a wide range of pharmacological activity.

Object of the invention is the expansion of the range of medicines that have the property of correction of insulin resistance, no contraindications and allowing to reduce the frequency FOB is uncinata) as a means for the correction of insulin resistance.

The use of Mexidol as a means for the correction of insulin resistance allows to obtain the following technical result.

The drug "Mexidol allows you to expand the range of drugs with properties correction of insulin resistance. Significantly expands the scope of application of the drug in a variety of infections, schizophrenia, blood diseases, diabetes, cardiovascular diseases, acute and chronic inflammation, obesity.

This Mexidol allow to increase the effectiveness of hypoglycemic and hypolipidemic drugs, because it has a direct effect on carbohydrate and lipid metabolism.

A wide range of pharmacological activity of Mexidol allows to reduce the number entered in the complex with it's antibacterial, anti-inflammatory, fibrinolytic, anxiolytic, antidiabetic drugs, as well as the means of correcting lipid metabolism, which helps to reduce the frequency of adverse reactions.

Mexidol virtually no side effects, so it can be applied by patients over 70 years of age and adolescents.

Use of the drug "Mexidol" has the man as the main pathogenetic link insulin resistance. Mexidol through the influence of the coupling of respiration and oxidative phosphorylation can be stimulated by direct oxidation of glucose in the pentose-phosphate shunt, stabilizing glutathione-glutationreductaza system and activate metabolic processes in the endoplasmic reticulum, promote the metabolism of fatty acids, phospholipids, prostaglandins. Important properties of Mexidol is its ability to enhance detoxification processes, to improve the rheological properties of the blood, stimulate the humoral link of nonspecific protection, provide anti-inflammatory and antibacterial effects. All of the above gives grounds to consider Mexidol as a promising drug for the correction of metabolic disorders (including insulin resistance) in various diseases (obesity, and cerebral infarction, ischemic heart disease, diabetes).

The drug is well combined with hypoglycemic drugs, lipid-lowering, anti-inflammatory drugs, fibrinolytic and thrombolytic drugs, as well as tools that have an impact on blood rheology.

The possibility of correcting Mexicola the Insa is found insulin resistance, is achieved through a direct effect on lipid metabolism through the mobilization of lipids from the fat depots with subsequent oxidation of fatty acids. This reduces the level of free fatty acids, normalization ratio atherogenic and antiatherogenic lipoprotein fractions (decrease lipoproteins of low and very low density and increase high-density lipoprotein), lower concentrations of triglycerides and total cholesterol in the blood. In addition, Mexidol increases tissue sensitivity to insulin by stimulating the direct oxidation of glucose in the pentose-phosphate shunt, thereby reducing glucosetolerance in relation to the glucose transporters (particularly GLUT4), insulin receptors and enzymes.

Apply Mexidol as a means for the correction of insulin resistance as follows.

Depending on the severity of the disorders of carbohydrate and lipid metabolism Mexidol injected into the body intramuscularly and/or oral. The dose depends on the disease stage and severity of its course. On average, Mexidol is administered in a dose of 100-200 mg daily for 5-7 days for a course of treatment, if necessary, repeat after 2-4 months. For example, nutramigen within 3-5 days. Possible oral (capsule form) with atherosclerosis of the coronary arteries, the vessels of the brain in diabetes mellitus type 2, 100 mg 2 times a day for 5-7 days.

Example 1. Patient C., 65 years.

Was admitted with complaints of dry mouth, aching pain in the legs at night.

At the examination: height 163 see Weight 84 kg, the skin is a normal color, dry. In the lungs vesicular breathing, wheezing no. Heart sounds rhythmic, muted, accent of II tone of the aorta. AD-150/80 mm RT.article The heart rate of 68 beats/min Abdominal palpation painless and soft in all departments, the liver is not enlarged. The lumbar area is not visually changed, symptom tapping negative on both sides, dysuria no.

Diagnosis: diabetes of the 2nd type, moderate. The stage of decompensation. Obesity class II).

Clinical and laboratory studies:

(before treatment with Mexidol)

CBC - without pathology

Clinical urine analysis showed no pathology

Blood biochemistry: ALT - 45 IU/l, ACT - 27 IU/l, alkaline phosphatase - 106 IU/l, XC - 6,92 mmol/l, TG - 3.88 mmol/l, creatinine - 86 Ámol/l, urea - 6,6 Glycemic profile: 900with 12.3, 12, 0mm; 1300- 11,9, 11,8; 1700and 12.4, and 12.5; 2100- 13,5, 12,7; 600to 12.5 and 11.2.

Consultation of the oculist: Diabetic retinopathy stages I-II. Palpate both eyes. Ongoing therapy: Diet N 8 (1800 kcal), glurenorm 0.3 2 tab. morning and evening, Enap 10 mg 1 tab. in the morning, mazindol 0.001 mg - 1 t/day acetylsalicylic acid 1/4 t in the morning.

Given the lack of effect of therapy glucose-lowering drugs, the patient was offered a transfer to insulin. In connection with failure patients on insulin therapy, it was decided to appoint Mexidol. Mexidol has appointed intramuscularly at a dose of 200 mg/day for 3 days, followed by oral administration of 100 mg for the next 4 days (1000 mg per treatment). To assess therapeutic effect of Mexidol were cancelled mazindol and acetylsalicylic acid. The patient continued to take glurenorm 0.3 2 tab. morning and evening, Enap 10 mg 1 tab. morning.

The treatment efficacy was observed on day 5 after administration of Mexidol and was expressed in the following:

The glycemic profile:

on the 5th day - 900- 7,2; 1300- 6,9; 1700- 6,7; 2100- 7,1; 600- 8.1 (mmol/l) blood glucose profile on the 10th day after receiving Mexidol: 9

The glycemic profile on the 12th day of the 900- 6,7; 1300- 6,1; 1700- 6,4; 2100- 6,6; 600- 7,5 (mmol/l)

on the 15th day of the 900- 5,7; 1300- 6,6; 1700- 6,2; 2100- 6,3; 600- 7,1 (mmol/l)

Biochemical analysis of blood (see tab. 1).

Examination by ophthalmologist:

Negative dynamics in the fundus of the eye during the test observations.

The patient was discharged from the hospital with a diagnosis of diabetes mellitus type 2, moderate in state compensation. Diabetic microangiopathy: diabetic retinopathy stages I-II. Diabetic distal polyneuropathy form touch type. Alimentary obesity class II).

Patient recommended: a diet low in animal fats and refined carbohydrates (1800 kcal), pragian 1 t in the morning and evening; Enap 10 mg 1 tab. in the morning. A second course of Mexidol is supposed to spend 2 months. Frequency of courses will depend on the condition of the patient (assessment of the level of glycemia, lipid spectrum and level IRI).

Example 2. Patient M., 46 years old.

Was admitted with complaints of acute encircling the pain in the left pojebani, vomiting.

When the inspection is Mary, muted, the accent of II tone of the aorta. AD-160/85 mm RT.article Heart rate is 90 beats/min Abdominal palpation painful tightening of the muscles of the abdominal wall in all departments, the liver is not enlarged. The lumbar area is not visually changed, symptom tapping negative on both sides, dysuria no.

Diagnosis (intraoperative): Acute hemorrhagic pancreatic necrosis. Enzymatic peritonitis. Intoxication, 2-sided jet pleurisy.

Clinical and laboratory studies:

(before treatment with Mexidol)

CBC - hemoglobin -102, ESR 68, the remaining indicators without pathology

Clinical urine analysis showed no pathology

Blood biochemistry: ALT - 27 IU/l, AST - 11 IU/l, alkaline phosphatase - 84 IU/l, LDL - 6,88 mmol/l, TG - 3.58 mmol/l, creatinine - 102 Ámol/l amylase blood - 907 g/CASL (N 25-80)

The glycemic profile: 900- 11,9; 1300- 12,4; 1700- 11,9; 2100- 12,8; 60011.2 in.

Ultrasound at receipt: Liver - without a pathology. Gall bladder 6,h,8 cm, thickened wall of the lumen homogeneous. Choledoch has a bend, not expanded. The pancreas is almost not visualized due to pneumatization loops of bowel, the head 33 mm, multiple heterogeneous structure.

Laporan, edematous.

Conclusion: acute fatty pancreonecrosis.

Emergency surgery: Laparotomy. Sequestrectomy. Cholecystostomy. Drainage stuffing bags. Sanitation and drainage stuffing bags. Pancreas: in the area of head, body and tail of the necrotic tissue black, large number of plaques stefanakos.

Held in the postoperative period therapy:

Mexidol - 200 mg intramuscularly 2 times a day for 4 days, contrical, Actovegin, gentamicin, vitamin therapy (standard dose)

The treatment efficacy was celebrated on the 5th day of reception of Mexidol and was expressed in the following:

The glycemic profile:

on the 5th day - 900- 6,7; 1300- 7,7 1700- 6,2; 2100- 7,4; 600- 7,1(mmol/l)

The glycemic profile on the 10th day after receiving Mexidol: 900- 6,1; 1300- 5,8; 1700- 6,0; 2100- 5,9; 600- 5,4 (mmol/l)

on the 14th day of the 900- 4,6; 1300- 5,8; 1700- 4,5; 2100- 5,5; 600- 4,7 (mmol/l)

on the 15th day of the 900- 4,3; 1300- 5,2; 1700- 5,0; 2100- 4,8; 600- 4,0 (mmol/l)

on the 30th day 900- 4,3; 1300- 5,3; 1700and 4.4; 2100- 4,7; 600to 4.5 (m is imicheskij blood (see table. 2).

Ultrasound on day 14 after surgery: Pancreas is visualized bad in the body thickened up to 42 mm, moderately heterogeneous. Saved a small amount of fluid in the spleen and in the pleural cavity.

Ultrasound at 30 days after surgery: Liver, gall bladder intact. The pancreas is poorly visualized in the body and tail. Free liquid is determined only by the spleen, pleural cavity free.

Ultrasound at 60 days after surgery: a Positive trend. Pancreas agogino heterogeneous, HH mm Free liquid not determined. Changes retroperitoneal space is not revealed.

In connection with the stabilization of the state, elimination of acute inflammation and its associated insulin resistance, the patient was discharged in satisfactory condition.

The use of Mexidol (2-ethyl-6-methyl-3-oksipiridina succinate) as a means for the correction of insulin resistance.


Same patents:

Antibacterial // 2157686
The invention relates to the field of medicine

The invention relates to medicine, namely to infectious diseases, and is intended for the treatment of patients with common and toxic form of diphtheria
The invention relates to physiologically active compounds and relates amidoalkylation and method of production thereof

FIELD: medicine, immunology, narcology, biochemistry.

SUBSTANCE: invention elates to correction of immune disturbances in opium narcomania. Method is carried out by administration of an immunomodulating agent, 2-ethyl-6-methyl-3-oxypyridine succinate, in period for arresting opium abstinent syndrome by intravenous route, 2 times per a day in daily dose 0.1-0.4 g for 5-7 days, and at the stage of post-abstinent state - by intramuscular route in daily dose 0.1-0.2 g, 2 times per a day for 7-14 days, and at the reablement stage - by intramuscular route in daily dose 0.1-0.2 g every other day for 3-4 weeks. Method provides reducing activity of lymphocyte NO-synthase and normalization of immunocytogram picture.

EFFECT: improved method for correction.

2 ex

FIELD: medicine, cosmetology.

SUBSTANCE: the suggested wound-healing remedy includes a gel-forming agent, an active substance and distilled (deionized) water. As the active substance it contains Mexidol (2-ethyl 6-methyl 3-oxypyrridine succinate) at the following ratio of components, weight%: gel-forming agent 0.5-5.0, stabilizing agent 0.01-0.8, conservant 0.01-1.0, Mexidol 0.01-10.0, distilled (deionized) water - the rest. The suggested remedy is highly efficient. It is of pronounced wound-healing action in 1, 2 and 3 phases of wound process. It quickly liquidates inflammatory processes, decreases painfulness, edema, considerably improves the state of affected tissues, accelerates reparative-degenerative processes and terms of epithelization. It possesses the wide spectrum of action, manifests pronounced action at treating different skin and mucosal lesions - wounds, fissures, bedsores, trophic ulcers of different genesis, surface burns of 1-3 degree, radiation lesions, it, also, removes skin microlesions that possess the nature of cosmetic defects, moreover, it improves skin structure.

EFFECT: higher efficiency of application.

2 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves intravenous administration of metypred in every other day being in the 1-st and 3-d days the dose is by 500.0 mg, in 5-th and 7-th day - by 250.0 mg, and in 9-th and 10-th day - by 125 mg. In onset of metypred administration dexamethasone in the dose 1.0 ml is administrated by retrobulbar route every day for 10 days. Also, method involves pterygopalatine blockade including dexamethasone, ketorol, emoxipine, lidocaine, dalargin in doses 1.0; 1.0; 1.0; 2.0 ml and 0.001 g every day for 5 days and then 3 blockades in every other day, one blockade per a day. Method expands assortment of therapeutic approaches in treatment of acute optical neuritis in patients with cerebrospinal sclerosis.

EFFECT: improved and enhanced treatment method.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

FIELD: medicine.

SUBSTANCE: method involves introducing Mirtilene forte at a dose of 1 pill twice a day and 1% Emoxipini solution at a parabulbar dose of daily as drug therapy component in combined treatment course comprising also magnetic therapy, laser stimulation of macular retina zone and pattern-stimulation. The total treatment course is 10 days long.

EFFECT: enhanced effectiveness of treatment.

2 cl

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: one should correct hemostasis disorders intra-operationally due to introducing fraxiparine about 40-80 min against the onset of operation along with intravenous injection of mexidol, by drops at the dosage of about 5-6 mg/kg patient's body weight dissolved in 400 ml 0.9%-NaCl solution at the rate of 60 drops/min. The present innovation enables to create the peak of fraxiparine and mexidol concentrations at traumatic stage of operation that enables to correct hemostasiological disorders during operative interference and at early post-operational period due to combined action of preparations onto different links of hemostasis.

EFFECT: higher efficiency and accuracy of correction.

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with treating acute anterior and posterior ischemic optic neuropathy due to introducing vasodilators and anticoagulants as caffeine, halidor, dicinon in complex therapy in hospital for 10 d. Moreover, it is necessary to perform parabulbar introduction of 0.3 ml dexasone, 0.2 ml caffeine, 0.3 ml emoxipin successively, fractionally every 20 min once daily in combination with daily intramuscular injections once daily of 2.0 ml dicinon and 1.0 ml halidor and intravenous injection of haemodesum by drops per 200.0 ml on the 1st, 3d and 5th d of therapy. Also, it is necessary to carry out 5 seances of hirudotherapy for temple area every other day under coagulogram control. Then one should introduce milgamma, dicinon and nootropil at age-dependent dosages for 1 mo ambulatorily. The innovation provides complex improvement of microcirculation and metabolicocular and cerebral processes, regeneration of nervous tissue and reconstruction of optic nerve's conductivity at decreased frequency of therapeutic side effects.

EFFECT: higher efficiency of therapy.

2 ex, 1 tbl

FIELD: medicine, gynecology.

SUBSTANCE: invention relates to a method for correction of vegetative symptoms in climacteric syndrome in women with ischemic disorders in cerebral circulation. Method involves administration of mexidol in the dose 125 mg, 3 times per a day for 8 weeks, and alzolam in the dose 0.25 mg, once per a day, 30 min before sleeping for 4 weeks. Method represents the alternative substitution hormonal therapy and provides the simultaneous correction of vegetative disorders in climacteric period and ischemic damages of the cerebral circulation.

EFFECT: improved method of syndrome correction.

1 tbl

FIELD: organic chemistry, medicine, rheumatology.

SUBSTANCE: invention proposes a medicinal agent comprising derivative of aminostilbazol as an active component of the formula : or its salt wherein G represents phenyl optionally substituted with (C1-C6)-alkoxy-group; R represents (1) hydrogen atom, (2) (C1-C6)-hydroxyalkyl, or (3) the group -CORo wherein Ro represents (C1-C6)-alkyl, (C1-C6)-alkoxy-, phenoxy-group. The preferable compound is (E)-4-{2-[2-{N-acetyl-N-[(4-methoxyphenyl)sulfonyl]amino}phenyl]ethenyl}pyridine 1-oxide. The proposed agent is designated for treatment of chronic articular rheumatism.

EFFECT: realization of invention, valuable medicinal properties of agent.

7 cl, 2 tbl, 7 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves carrying out the lymphotropic therapy by submastoidal (parotid) blockades including course of 6-8 procedures every day by using the following medicinal mixture comprising, mg: lidocaine, 50-100; cortexin, 10-20; dalargin, 0.001-0.002; mexidol, 50-100; lydazum, 16-32 U, and additional 3-4 procedures of discrete plasmapheresis with interval for 48-72 h; exfusion value for a single procedure is 20-25% of volume of circulating plasma, not above. The separated cellular mass is activated by incubation with 300-500 mg of preparation mildronate in thermostat at temperature 36.6-37.0°C for 30-40 min followed by reinfusion into the general blood stream. Method provides elimination of the cause in progressing the glaucoma optical neuropathy based on high region exposition and concentration of medicinal preparations on background of detoxifying, hemorheological and immunotropic effect of plasmapheresis.

EFFECT: improved method of treatment.

2 cl, 2 ex

FIELD: medicine, endocrinology.

SUBSTANCE: invention relates to methods used in treatment of the impaired glucose tolerance in aim for prophylaxis or postponement of invasion of insulin-independent diabetes mellitus. Variants of method involves administration in patient compounds of the formula (I) or (II) or their pharmaceutically acceptable salts describes in the invention claim, in particular, such compounds as (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione, pioglitazone, ciglitazone. Invention provides prevention of insulin-independent diabetes mellitus development by decrease of insulin insufficiency and normalization of tolerance to glucose in clinically health patients no having the enhanced basal levels of blood glucose.

EFFECT: improved treatment method.

9 cl, 4 tbl, 1 ex

FIELD: medicine, gastroenterology, pancreatology, reanimation.

SUBSTANCE: method involves carrying out epidural anesthesia at the level ThIX - ThXI with 0.2% ropivacaine solution that is administrated at the rate 4-5 ml/h for 72 h. Epidural infusion is combined with intravenous administration of the preparation "Essentiale" in the dose 10 ml of solution in 200 ml of 0.9% NaCl, 2 times per 24 h. Invention provides adequate anti-stress protection and analgesic effect and with retention of motor activity of patient. Invention can be used in treatment of acute destructive pancreatitis in early period.

EFFECT: improved and enhanced effectiveness of treatment.

1 ex

FIELD: medicine, endocrinology.

SUBSTANCE: therapeutically efficient quantities of phitostanol characterised by general formula I are introduced.

EFFECT: efficient treatment of sugar diabetes due to an increase in cell sensitivity to glucose and insulin and enhancing insulin secretion by beta-cells of pancreas.

4 ex, 10 dwg, 18 cl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, pharmacology and food industry and applies to medication, food product or drink for pancreas function improvement, which includes as active compound 4-methylholest7-en-3-ol, 4-methylergost-7-en-3-ol or 4-methylstigmast-7-en-3-ol, and method of pancreas function improvement.

EFFECT: invention ensures increased treatment efficiency.

19 cl, 3 tbl, 2 ex

FIELD: chemistry, biochemistry.

SUBSTANCE: invention refers to biotechnology, specifically, to cell differentiation and can be used in medicine. Differentiated stromal cell is made of adipose tissue. This cell expresses one or more proteins, characteristic for endocrine pancreas cell, such as insulin, glucagon, somatostatin and pancreatic polypeptide.

EFFECT: production of differentiated and functionally relevant cell for researches, implantation, transplantation and development of tissue products for treating pancreas diseases and repairing pancreas tissues.

24 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, pharmaceutics and food industry and concerns a medical product, foodstuff or a beverage for pancreas improvement, containing compounds 9,19-cyclolanostan-3-ol and-or 24-methylene-9,19-cyclolanostan-3-ol as an active compound, and pancreas improvement method.

EFFECT: invention ensures improved clinical effectiveness.

19 cl, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to haematology cardiology and endocrinology, and concerns correction of blood microvesicle level in abdominal obesity. That is ensured by patient-specific hypocaloric diet combined with graduated physical exercises and preparation Orlistat introduced in a dose 120 mg 3 times a day with food intake. Therapeutic course is at least 12 weeks.

EFFECT: method enables normalisation and following maintenance of blood microvesicle level, and thereby prevention of vascular complications in patients of given category.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to agonists of neuropeptide-2 receptor with formula (I): Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2(l), as well as their pharmaceutically acceptable salts, derivatives and fragments, in which substitutes assume values given in the description.

EFFECT: compounds and pharmaceutical compositions containing said compounds can be used to treat diseases which are modulated by neuropeptide-2 receptors, mainly obesity.

13 cl, 10 dwg, 1 tbl, 74 ex